Zhu C, Zhou Z, Roos I, Merlo D, et al. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2022 Oct 19. pii: jnnp-2022-330104.
PMID: 36261289